Neogen (NEOG) Received An FDA Warning Over Contaminated Veterinary Product

• Neogen (NasdaqGS:NEOG) received a formal FDA warning letter tied to contamination issues in its HYCOAT(R) veterinary product.

• Regulators cited significant manufacturing violations at HYCOAT(R) production facilities that they linked to serious adverse events in horses.

• The FDA findings referenced multiple horse deaths following HYCOAT(R) use and triggered a recall of affected product lots.

• The HYCOAT(R) contamination and FDA warning letter give important context, but investors need a wider view of Neogen's position. Take a look at 1 warning sign we have identified for Neogen.

Consider widening the lens by exploring other veterinary and broader healthcare exposures alongside 34 healthcare AI stocks .

Neogen operates as a US based medical equipment provider focused on food and animal safety products across global markets, so quality control in veterinary offerings such as HYCOAT(R) is central to what customers expect from the business.

See how Neogen's balance sheet measures up .

How serious is this FDA warning for Neogen's operations and finances right now?

The FDA describes the HYCOAT issue as involving the largest number of deaths linked to a veterinary medical product quality defect, which signals material compliance concerns. HYCOAT relied on a contract manufacturer that the agency says operated under insanitary conditions, so Neogen now faces remediation costs, potential write offs and possible restrictions on future product distribution if responses fall short.

Does this change the Neogen Narrative investors have been following?

The Narrative for Neogen leans on tighter execution, cleaner operations and higher margin products after portfolio pruning and 3M Food Safety integration work. An FDA letter that highlights weak quality oversight of a third party cuts against the operational excellence and margin recovery angle in that story, especially with the business already reporting a net loss of US$11.9 million in the latest quarter and not expected to reach profitability over the next 3 years.

See how these catalysts shape Neogen's path to a $14.00 fair value .

How does the HYCOAT recall sit next to Neogen's recent earnings and new partnerships?

On 6 October 2026, Neogen reported US$222.8 million in quarterly revenue and still raised revenue guidance for fiscal 2027 to US$885 million to US$890 million, while also committing capital to Hinalea Imaging to develop digital inspection tools. The HYCOAT problems therefore land while Neogen is both loss making and investing in new technology, which could stretch management focus between growth projects and compliance fixes.